Genetic analysis for five LRRK2 mutations in a Sardinian parkinsonian population: importance of G2019S and R1441C mutations in sporadic Parkinson's disease patients
- PMID: 18805725
- DOI: 10.1016/j.parkreldis.2008.06.009
Genetic analysis for five LRRK2 mutations in a Sardinian parkinsonian population: importance of G2019S and R1441C mutations in sporadic Parkinson's disease patients
Abstract
Mutations in the LRRK2 gene are the most common known cause of familial and sporadic Parkinson's disease (PD). Few studies performed to date to assess frequency of these mutations are actually only representative of specific areas. Here we study the frequency and clinical phenotype of LRRK2 G2019S, I2020T and R1441C/G/H mutations in 356 Sardinian patients with idiopathic PD and 208 controls. Seventeen additional subjects, relatives of PD mutated probands, were enrolled. Eight patients were mutated in heterozygosis for LRRK2 gene (2.3%): six carried the G2019S (1.7%) and two the R1441C (0.6%) mutation. Three PD patients G2019S carriers (50%) were detected in two contiguous villages comprising 3921 inhabitants while the other three (50%) were identified in the remaining population of 796,079 inhabitants. Only one mutated proband had a family history of PD. LRRK2 G2019S and R1441C mutations associated with PD were not an uncommon mutation in a Sardinian population, especially in sporadic PD patients. The detection of the G2019S variant in ten unaffected relatives confirms a reduced penetrance of the underlying mutation and might explain its prevalence among patients with sporadic PD. These findings may provide new insights into the importance of studies of frequency of LRKK2 mutations in PD patients originating from small ethnically homogeneous populations.
Similar articles
-
LRRK2 mutations in Spanish patients with Parkinson disease: frequency, clinical features, and incomplete penetrance.Arch Neurol. 2006 Mar;63(3):377-82. doi: 10.1001/archneur.63.3.377. Arch Neurol. 2006. PMID: 16533964
-
Genetic screening for the LRRK2 R1441C and G2019S mutations in Parkinsonian patients from Campania.J Parkinsons Dis. 2014;4(1):123-8. doi: 10.3233/JPD-130312. J Parkinsons Dis. 2014. PMID: 24496098
-
Genetic screening for LRRK2 gene G2019S mutation in Parkinson's disease patients from Southern Italy.Parkinsonism Relat Disord. 2009 Mar;15(3):242-4. doi: 10.1016/j.parkreldis.2008.05.011. Epub 2008 Jul 14. Parkinsonism Relat Disord. 2009. PMID: 18621566
-
LRRK2 G2019S in the North African population: a review.Eur Neurol. 2010;63(6):321-5. doi: 10.1159/000279653. Epub 2010 Apr 23. Eur Neurol. 2010. PMID: 20413974 Review.
-
LRRK2 in Parkinson's disease: genetic and clinical studies from patients.FEBS J. 2009 Nov;276(22):6455-63. doi: 10.1111/j.1742-4658.2009.07344.x. Epub 2009 Oct 5. FEBS J. 2009. PMID: 19804413 Review.
Cited by
-
Overview of the Impact of Pathogenic LRRK2 Mutations in Parkinson's Disease.Biomolecules. 2023 May 16;13(5):845. doi: 10.3390/biom13050845. Biomolecules. 2023. PMID: 37238714 Free PMC article. Review.
-
Review of the epidemiology and variability of LRRK2 non-p.Gly2019Ser pathogenic mutations in Parkinson's disease.Front Neurosci. 2022 Sep 20;16:971270. doi: 10.3389/fnins.2022.971270. eCollection 2022. Front Neurosci. 2022. PMID: 36203807 Free PMC article. Review.
-
Reevaluation of phosphorylation sites in the Parkinson disease-associated leucine-rich repeat kinase 2.J Biol Chem. 2010 Sep 17;285(38):29569-76. doi: 10.1074/jbc.M110.127639. Epub 2010 Jul 1. J Biol Chem. 2010. PMID: 20595391 Free PMC article.
-
Orchestrating vesicular and nonvesicular membrane dynamics by intrinsically disordered proteins.EMBO Rep. 2023 Nov 6;24(11):e57758. doi: 10.15252/embr.202357758. Epub 2023 Sep 8. EMBO Rep. 2023. PMID: 37680133 Free PMC article. Review.
-
The LRRK2 G2019S mutation as the cause of Parkinson's disease in Ashkenazi Jews.J Neural Transm (Vienna). 2009 Nov;116(11):1473-82. doi: 10.1007/s00702-009-0303-0. J Neural Transm (Vienna). 2009. PMID: 19756366 Review.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical